Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Clin Cancer Res. 2009 Nov 17;15(23):7238–7245. doi: 10.1158/1078-0432.CCR-09-1964

Figure 2.

Figure 2

Effect of tetracycline and ciprofloxacin in vivo against lethal TBI. (A) Two intraperitoneal injections of tetracycline or ciprofloxacin at 24 h and 1 h prior to 8 Gy TBI protected mice from lethality. This effect was most prominent with tetracycline at 150 mg/kg (87.5% survival). (B) The same schedule of tetracycline treatment at 150 mg/kg as Fig. 2A protects the immunohematopoietic system from lethal TBI. Spleen weights and white cell counts were performed 3 d later and bone marrow cells were pooled from 4 mice per treatment group for assessment of granulocyte-macrophage colony forming units (Gm-CFU). The data from two separate experiments were shown (combined n=7 except tetracycline-treated group: n=4). * indicates P < 0.05 (IR vs IR+tetracycline). (C) 5 daily injections of tetracycline starting 24 h after 8 Gy TBI improves animal survival (P < 0.05), while ciprofloxacin failed as a mitigator. Number of mice in each treatment group is in parenthesis.